{{Chembox
| ImageFile = Plinabulin.svg
| ImageSize = 200px
| IUPACName = (3''Z'',6''Z'')-3-Benzylidene-6-{[5-(2-methyl-2-propanyl)-1''H''-imidazol-4-yl]methylene}-2,5-piperazinedione
| OtherNames = 
|Section1={{Chembox Identifiers
| CASNo = 714272-27-2
| CASNo_Ref = {{cascite|correct|}}
| PubChem = 9949641
| ChemSpiderID = 8125252
| KEGG = D09655
| SMILES = O=C3/C(=C/c1ncnc1C(C)(C)C)NC(=O)C(=C\c2ccccc2)\N3
| InChI = 1/C19H20N4O2/c1-19(2,3)16-13(20-11-21-16)10-15-18(25)22-14(17(24)23-15)9-12-7-5-4-6-8-12/h4-11H,1-3H3,(H,20,21)(H,22,25)(H,23,24)/b14-9-,15-10-
| InChIKey = UNRCMCRRFYFGFX-TYPNBTCFBU
| StdInChI = 1S/C19H20N4O2/c1-19(2,3)16-13(20-11-21-16)10-15-18(25)22-14(17(24)23-15)9-12-7-5-4-6-8-12/h4-11H,1-3H3,(H,20,21)(H,22,25)(H,23,24)/b14-9-,15-10-
| StdInChIKey = UNRCMCRRFYFGFX-TYPNBTCFSA-N
  }}
|Section2={{Chembox Properties
| C=19 | H=20 | N=4 | O=2
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility =
  }}
|Section3={{Chembox Hazards
| MainHazards = 
| FlashPt = 
| AutoignitionPt =
  }}
}}

'''Plinabulin''' ('''chemical structure, BPI-2358, formerly NPI-2358''') is a small molecule under development by BeyondSpring Pharmaceuticals, and is in a world-wide Phase 3 clinical trial for non-small cell lung cancer. 
<ref>{{cite web 
| url = https://clinicaltrials.gov/show/NCT02504489.
| title = Assessment of Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC With at Least One Measurable Lung Lesion (DUBLIN-3)
}}</ref> Plinabulin blocks the polymerization of tubulin in a unique manner, resulting in multi-factorial effects including an enhanced immune-oncology response, 
<ref>{{cite 
| last = Lloyd
| first = G.K.
| last2 = Muller
| first2 = Ph.
| last3 = Kashyap
| first3 = A.
| last4 = Zippelius
| first4 = A.
| last5 = Huang
| first5 = L.
| title = Plinabulin: Evidence for an Immune Mediated Mechanism of Action
| conference = Proceedings of the Meeting on the Function of Tumor Microenvironment in Cancer Progression
| date= January 7-9, 2016
| location = San Diego CA
| format = Philadelphia (PA) AACR 2016 Abstract nr A07
}}</ref> activation of the JNK pathway
<ref>{{cite journal
| last = Singh 
| first = A.V.
| last2 = Bandi 
| first2 = M.
| last3 = Raje 
| first3 = N.
| last4 = Richardson 
| first4 = P.
| last5 = Palladino 
| first5 = M.A.
| last6 = Chauhan
| first6 = D.
| last7 = Anderson
| first7 = K.
| title      =   A Novel Vascular Disrupting Agent Plinabulin Triggers JNK-Mediated Apoptosis and Inhibits Angiogenesis in Multiple Myeloma Cells
| url = http://www.bloodjournal.org/content/117/21/5692 
| journal    =  Blood
| year = 2011
| volume     = 117
| issue      = 21
| pages      = 5692-5700

}}</ref> and disruption of the tumor blood supply. Plinabulin is being investigated for the reduction of chemotherapy-induced neutropenia
<ref>{{cite 
| title = Randomized Phase 2 Trial of Plinabulin (NPI-2358) Plus Docetaxel in Patients with Advanced Non-Small Lung Cancer (NSCLC)
| last = Heist
| first = R.S.
| last2 = Aren
| first2 = O.R.
| last3 = Mita
| first3 = A.C.
| last4 = Polikoff
| first4 = J.
| last5 = Bazhenova
| first5 = L.
| last6 = Lloyd
| first6 = G.K.
| last7 = Mikrut
| first7 = W.
| last8 = Reich
| first8 =W.
| last9 = Spear
| first9 = M.A.
| last10 = Huang
| first10 = L.
| year = 2014
| conference = J Clin Oncol 32:5s
| editor =
| format =  abstr 8054
| volume =
| edition =
| book-title =
| publisher =
| archive-url =
| archive-date =
}}</ref> and for anti-cancer effects in combination with immune checkpoint inhibitors 
<ref>{{cite web
| url = https://clinicaltrials.gov/show/NCT02846792 
| title = Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer
}}</ref>
<ref>{{cite web
| url = https://clinicaltrials.gov/show/NCT02812667 
| title = Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
}}</ref> and in KRAS mutated tumors.
<ref>{{cite 
| title = Activity of Plinabulin in Tumor Models with Kras Mutations
| last = Lloyd
| first = G.K.
| last2 = Du
| first2 = L.
| last3 = Lee
| first3 = G.
| last4 = Dalsing-Hernandez
| first4 = J.
| last5 = Kotlarczyk
| first5 = K.
| last6 = Gonzalez
| first6 = K.
| last7 = Nawrocki
| first7 = S.
| last8 = Carew
| first8 = J.
| last9 = Huang
| first9= L.
| date = October 5-9, 2015
| conference = Proceedings of the International Conference on Molecular Targets and Cancer Therapeutics
| location = Boston MA
| format = Philadelphia (PA) AACR 2015 Abstract nr. 184
}}</ref> 


==References==
{{reflist}}

[[Category:Diketopiperazines]]
[[Category:Imidazoles]]
[[Category:Experimental cancer drugs]]